Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk. Read more about Circulating tumor DNA and magnetic resonance imaging to predict neoadjuvant chemotherapy response and recurrence risk.
Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma. Read more about Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry. Read more about Ancestry-associated transcriptomic profiles of breast cancer in patients of African, Arab, and European ancestry.
MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit. Read more about MCM3 upregulation confers endocrine resistance in breast cancer and is a predictive marker of diminished tamoxifen benefit.
Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL. Read more about Predicting breast cancer response to neoadjuvant treatment using multi-feature MRI: results from the I-SPY 2 TRIAL.
The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology. Read more about The quality of life index: a pilot study integrating treatment efficacy and quality of life in oncology.
Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial. Read more about Mechanism of action biomarkers predicting response to AKT inhibition in the I-SPY 2 breast cancer trial.
Androgen receptor gene expression in primary breast cancer. Read more about Androgen receptor gene expression in primary breast cancer.
Androgen receptor gene expression in primary breast cancer. Read more about Androgen receptor gene expression in primary breast cancer.
The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Read more about The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer.
